ANAVEX LIFE SCIENCES CORP.
Business
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company developing differentiated therapeutics for central nervous system diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and rare neurodevelopmental disorders. The company's pipeline centers on ANAVEX®2-73 (blarcamesine), a sigma-1 receptor agonist in multiple clinical trials, and ANAVEX®3-71, targeting SIGMAR1 activation and M1 muscarinic modulation. The company employs precision medicine and genomic biomarker analysis to identify patient populations most likely to benefit from treatment.
Summary from 10-K filed 2025-11-25
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| General and administrative | 14 | 11 | 12 | 13 | 9 | |
| Research and development | 38 | 42 | 44 | 38 | 33 | |
| Total operating expenses | 51 | 53 | 56 | 51 | 42 | |
| Operating loss | −51 | −53 | −56 | −51 | −42 | |
| Grant income | 37,000 | 75,000 | 25,000 | — | 54,000 | |
| Research and development incentive income | 648,000 | 2 | 3 | 3 | 5 | |
| Interest income, net | 5 | 7 | 7 | 947,000 | 26,000 | |
| Other financing expense | — | — | −964,000 | — | — | |
| Foreign exchange gain (loss) | −332,000 | 189,000 | −40,000 | −904,000 | −266,000 | |
| Total other income, net | 5 | 10 | 8 | 3 | 4 | |
| Net loss and comprehensive loss | −46 | −43 | −48 | −48 | −38 | |
| Net Loss per share, Basic | −0.54 | −0.52 | −0.6 | −0.62 | −0.54 | |
| Net Loss per share, Diluted | −0.54 | −0.52 | −0.6 | −0.62 | −0.54 | |
| Weighted average number of shares outstanding, Basic | 85 | 83 | 80 | 77 | 70 | |
| Weighted average number of shares outstanding, Diluted | 85 | 83 | 80 | 77 | 70 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 103 | 132 | 151 | 149 | 152 | |
| Incentive and tax receivables | 809,000 | 2 | 3 | 3 | 9 | |
| Prepaid expenses and other current assets | 429,000 | 931,000 | 653,000 | 354,000 | 371,914 | |
| Total Assets | 104 | 136 | 154 | 153 | 162 | |
| Accounts payable | 4 | 10 | 4 | 4 | 5 | |
| Accrued liabilities - Note 3 | 4 | 5 | 7 | 6 | 6 | |
| Deferred grant income - Note 4 | 805,000 | 842,000 | 917,000 | 444,000 | 443,831 | |
| Total Liabilities | 9 | 15 | 13 | 10 | 11 | |
| Capital stock Authorized:10,000,000 preferred stock, par value $0.001 per share | — | — | — | — | — | |
| Capital stock Authorized: 200,000,000 common stock, par value $0.001 per share Issued and outstanding: 86,668,521 common shares (2024 - 84,795,517) | 87,000 | 85,000 | 82,000 | 78,000 | 75,920 | |
| Additional paid-in capital | 477 | 456 | 435 | 388 | 348 | |
| Accumulated deficit | −382 | −336 | −293 | −246 | −198 | |
| Total Stockholders Equity | 95 | 120 | 142 | 142 | 151 | |
| Total Liabilities and Stockholders Equity | 104 | 136 | 154 | 153 | 162 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Non cash financing related charges | — | — | 845,000 | — | — | |
| Share based compensation | 12 | 9 | 16 | 18 | 8 | |
| Incentive and tax receivables | 2 | 260,000 | 484,000 | 6 | −4 | |
| Prepaid expenses and deposits | 502,000 | −278,000 | −299,000 | 1,000 | 88,000 | |
| Accounts payable | −5 | 5 | 497,000 | −914,000 | 751,000 | |
| Accrued liabilities | −943,000 | −2 | 1 | 330,000 | 2 | |
| Deferred grant income | −37,000 | −75,000 | 473,000 | — | 444,000 | |
| Net cash used in operating activities | −39 | −31 | −28 | −24 | −30 | |
| Issuance of common shares, net of share issue costs | 9 | 11 | 28 | — | — | |
| Payment for taxes related to cashless exercise of options | −3 | — | — | — | — | |
| Proceeds from exercise of stock options | 3 | 691,000 | 2 | 1 | 4 | |
| Net cash provided by financing activities | 9 | 12 | 30 | 21 | 153 | |
| (Decrease) Increase in cash and cash equivalents during the year | −30 | −19 | 2 | −3 | 123 | |
| Cash paid for state and local franchise taxes | 125,000 | 300,000 | 136,000 | — | — | |
| Common stock issued upon cashless exercise of stock options | 1 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is ANAVEX LIFE SCIENCES CORP.'s CIK number?
ANAVEX LIFE SCIENCES CORP.'s SEC CIK number is 0001314052 (1314052). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ANAVEX LIFE SCIENCES CORP.'s SEC filings?
All of ANAVEX LIFE SCIENCES CORP.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did ANAVEX LIFE SCIENCES CORP. last report earnings?
ANAVEX LIFE SCIENCES CORP. (AVXL) most recently filed an earnings 8-K with the SEC on Feb 9, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001731122-26-000193). This is ANAVEX LIFE SCIENCES CORP.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is ANAVEX LIFE SCIENCES CORP.'s most recent earnings 8-K?
ANAVEX LIFE SCIENCES CORP.'s latest earnings 8-K (Item 2.02) was filed Feb 9, 2026 under accession 0001731122-26-000193. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View ANAVEX LIFE SCIENCES CORP.'s latest earnings 8-K →
Look up any company's CIK number →